Overview

Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of SR121463B in correcting hyponatremia in patients with syndrome of inappropriate antidiuretic secretion (SIADH).To assess the long-term efficacy of SR121463B in maintaining normal levels of serum sodium in patients with SIADH. To assess the safety and tolerability of SR121463B in patients with SIADH. The double blind period is followed by an open label extension study with flexible doses of satavaptan.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Arginine Vasopressin
Hormones
Satavaptan
Vasopressins